Dr. Leslie Discusses CAR T-Cell Therapy in MCL

Lori A. Leslie, MD
Published: Tuesday, Apr 03, 2018



Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses the developing role of chimeric antigen receptor (CAR) T-cell therapy for patients with mantle cell lymphoma (MCL).

CAR T-cell therapy is an exciting advancement across lymphoma subtypes, with recently approved constructs in the diffuse large B-cell lymphoma subtype (DLBCL), says Leslie. There are ongoing trials in MCL that show promising efficacy in heavily pretreated patients.

In terms of patients with indolent lymphoma, CAR T-cell therapy is interesting because patients get too sick before they are able to receive the infusion of cells. Although the data are limited, there are excellent results, and patients can stay well enough to receive treatment. Hopefully this can be a curative treatment for this group of patients, Leslie adds.
 
SELECTED
LANGUAGE


Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses the developing role of chimeric antigen receptor (CAR) T-cell therapy for patients with mantle cell lymphoma (MCL).

CAR T-cell therapy is an exciting advancement across lymphoma subtypes, with recently approved constructs in the diffuse large B-cell lymphoma subtype (DLBCL), says Leslie. There are ongoing trials in MCL that show promising efficacy in heavily pretreated patients.

In terms of patients with indolent lymphoma, CAR T-cell therapy is interesting because patients get too sick before they are able to receive the infusion of cells. Although the data are limited, there are excellent results, and patients can stay well enough to receive treatment. Hopefully this can be a curative treatment for this group of patients, Leslie adds.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x